Systematic review and meta-analysis: Renin-angiotensin system inhibitors in the prevention of atrial fibrillation recurrences. an unfulfilled hope

Cardiovascular Drugs and Therapy

Volumn 26, Issue 1, 2012, Pages 47-54

  Disertori, Marcello ^a   Barlera, Simona ^b   Staszewsky, Lidia ^b   Latini, Roberto ^b   Quintarelli, Silvia ^a   Franzosi, Maria Grazia ^b  

^a SANTA CHIARA HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Atrial fibrillation secondary prevention; Atrial remodeling; Upstream therapy

Indexed keywords

AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; VALSARTAN;

ARTICLE; DRUG EFFICACY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SECONDARY PREVENTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84857784284     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6346-0     Document Type: Article

References (33)

1. AJ Camm P Kirchhof GYH Lip, et al. 2010 Guidelines for management of atrial fibrillation. The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2369 429 20802247 10.1093/eurheartj/ehq278
2. MC Wijffels CJ Kirchhof R Dorland, et al. 1995 Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats Circulation 92 1954 68 7671380 1:STN:280:DyaK2MvgtFemtg%3D%3D
3. M Allessie J Ausma U Schotten 2002 Electrical, contractile and structural remodeling during atrial fibrillation Cardiovasc Res 54 230 46 12062329 10.1016/S0008-6363(02)00258-4 1:CAS:528:DC%2BD38XivF2qs7Y%3D (Pubitemid 34327903)
4. D Li K Shinagawa L Pang, et al. 2001 Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure Circulation 104 2608 14 11714658 10.1161/hc4601.099402 1:CAS:528:DC%2BD38Xht1Cjtg%3D%3D (Pubitemid 33104801)
5. K Kumagai H Nakashima H Urata, et al. 2003 Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation J Am Coll Cardiol 41 2197 204 12821247 10.1016/S0735-1097(03)00464- 9 1:CAS:528:DC%2BD3sXnvVSqsb4%3D (Pubitemid 36724267)
6. E Vermes JC Tardif MG Bourassa, et al. 2003 Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials Circulation 107 2926 31 12771010 10.1161/01.CIR.0000072793.81076.D4 (Pubitemid 36736634)
7. AP Maggioni R Latini PE Carson, et al. 2005 Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT) Am Heart J 149 548 57 15864246 10.1016/j.ahj.2004.09.033 1:CAS:528:DC%2BD2MXis1GktLo%3D (Pubitemid 40585420)
8. A Ducharme K Swedberg MA Pfeffer, et al. 2006 Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program Am Heart J 152 86 92 16838426 10.1016/j.ahj.2005.06. 036
9. K Wachtell M Lehto E Gerdts, et al. 2005 Aangiotensin II receptor blokade reduces new-onset atrial fibillation and subsequent stroke compared to atenolol: the Losartan Intervention for end point reduction in hypertension (LIFE) study J Am Coll Cardiol 45 712 9 15734615 10.1016/j.jacc.2004.10.068 1:CAS:528:DC%2BD2MXhslegsLo%3D (Pubitemid 40282586)
10. MP Van Den Berg HJ Crijns DJ Van Veldhuisen, et al. 1995 Effects of lisinipril in patients with heart failure and chronic atrial fibrillation J Card Fail 1 355 63 10.1016/S1071-9164(05)80004-1
11. AH Madrid MG Bueno JM Rebollo, et al. 2002 Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study Circulation 106 331 6 12119249 10.1161/01.CIR.0000022665.18619.83 1:CAS:528:DC%2BD38Xmt1Whs7k%3D (Pubitemid 34778957)
12. KC Ueng TP Tsai WC Yu, et al. 2003 Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study Eur Heart J 24 2090 8 14643269 10.1016/j.ehj.2003.08.014 1:CAS:528:DC%2BD3sXptF2qsb4%3D (Pubitemid 37486528)
13. Y Yin D Dalal Z Liu, et al. 2006 Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation Eur Heart J 27 1841 6 16825288 10.1093/eurheartj/ehl135 1:CAS:528:DC%2BD28Xpt1yltLs%3D (Pubitemid 44297391)
14. JS Healey A Baranchuk E Crystal, et al. 2005 Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a metanalysis J Am Coll Cardiol 45 1832 9 15936615 10.1016/j.jacc.2004.11.070 1:CAS:528:DC%2BD2MXpsVCqt7s%3D (Pubitemid 40789940)
15. MP Schneider TA Hua M Bohm, et al. 2010 Prevention of atrial fibrillation by renin-angiotensin system inhibition J Am Coll Cardiol 55 2299 309 20488299 10.1016/j.jacc.2010.01.043
16. The GISSI-AF Investigators 2009 Valsartan for prevention of recurrent atrial fibrillation N Engl J Med 360 1606 17 10.1056/NEJMoa0805710
17. Goette A, Schon N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF)-trial. (Abstr). Hotline III ESC 2010; p. 3772.
18. ACTIVE I Investigators The 2011 Irbesartan in patients with atrial fibrillation N Engl J Med 364 928 38 10.1056/NEJMoa1008816
19. D Moher A Liberati J Tetzlaff DG Altman 2009 Preferred reporting items for systematic review and meta-analysis: the PRISMA statement J Clin Epidemiol 62 1006 12 19631508 10.1016/j.jclinepi.2009.06.005
20. F Belluzzi L Sernesi P Preti, et al. 2009 Prevention of recurrent lone atrial fibrillation by angiotensin-II converting enzyme inhibitor Ramipril in normotensive patients J Am Coll Cardiol 53 24 9 19118720 10.1016/j.jacc.2008.08. 071 1:CAS:528:DC%2BD1MXht1aqtw%3D%3D
21. A Tveit I Grundvold M Olufsen, et al. 2007 Candesartan in the prevention of relapsing atrial fibrillation Int J Cardiol 120 85 91 17113170 10.1016/j.ijcard.2006.08.086 (Pubitemid 47008995)
22. R DerSimonian N Laird 1986 Meta-analysis in clinical trials Control Clin Trials 7 177 88 3802833 10.1016/0197-2456(86)90046-2 1:STN:280: DyaL2s7gsVamtA%3D%3D (Pubitemid 17189972)
23. P Kirchhof A Auricchio J Bax, et al. 2007 Outcome parameters for trials in atrial fibrillation. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and European Heart Rhythm Association Europace 9 1006 23 17897925 10.1093/europace/eum191 (Pubitemid 351773289)
24. JL Lau JPA Ioannidis N Terrin, et al. 2006 The case of misleading funnel plot BMJ 333 597 600 16974018 10.1136/bmj.333.7568.597
25. G Huang J-B Xu J-X Liu, et al. 2011 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis Eur J Clin Invest 41 719 33 21250983 10.1111/j.1365-2362.2010.02460.x
26. R Bhuriya M Singh A Sethi, et al. 2011 Prevention of recurrent atrial fibrillation with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a systematic review and meta-analysis of randomized trials J Cardiovasc Pharmacol Ther 16 178 84 21285399 10.1177/1074248410389045 1:CAS:528:DC%2BC3MXnslOjs7c%3D
27. T Yamashita H Inoue K Okumara, et al. 2011 Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study) Europace 13 473 9 21148662 10.1093/europace/euq439
28. KT Murray JN Rottman PG Arbogast, et al. 2004 Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM Heart Rhythm 1 669 75 15851238 10.1016/j.hrthm.2004.08.008 (Pubitemid 40028772)
29. M Palardy A Ducharme S Nattel, et al. 2008 Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation developement: insights from the Canadian Trial of Atrial Fibrillation (CTAF) Can J Cardiol 24 709 13 18787722 10.1016/S0828-282X(08)70670-6
30. R Latini S Masson S Pirelli, et al. 2011 GISSI-AF Investigators. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-Atrial Fibrillation Trial J Intern Med 269 160 71 20964739 10.1111/j.1365-2796.2010.02287.x 1:STN:280:DC%2BC3M7gtFCnsg%3D%3D
31. S Masson A Aleksova C Favero, et al. 2010 Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI-atrial fibrillation trial Heart 96 1909 14 20965978 10.1136/hrt.2009.191460 1:CAS:528:DC%2BC3MXps1yl
32. Staszewsky L, Wong M, Masson S, et al. Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF Echocardiographic substudy. Circ Cardiovasc Imaging 2011; epub Sep 16, 2011. Circ Imaging111. 965954.
33. MCS Hall S Kirubakaran R Choudhury, et al. 2010 Effects of angiotensin receptor blokade on atrial electrical remodeling and the "second factor" in a goat burst-paced model of atrial fibrilation J Renin Angiotensin Aldosterone Syst 11 222 33 20507873 10.1177/1470320310369604 1:CAS:528:DC%2BC3MXmsVSgsw%3D%3D